2024
Targeted dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit
Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkuhle J, Espina V, Siwak D, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E, Liotta L, Mills G, Nishizuka S. Targeted dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit. Molecular & Cellular Proteomics 2024, 100870. PMID: 39461475, DOI: 10.1016/j.mcpro.2024.100870.Peer-Reviewed Original ResearchDNA-damaging drugsTotal lymphocyte countCell linesResistance to DNA damaging drugsPD-L1Adjuvant chemotherapyProtein dynamicsProtein-level regulationSurvival benefitCopy number lossExpression time courseGastric cancerRelapse-free survival rateGastric cancer cellsHost immunityAssociated with prolonged survivalIncreased STAT1 phosphorylationResistance to other drugsGlobal protein dynamicsImmune checkpoint blockadePD-L1 positivityPD-L1 expressionAdvanced gastric cancerExpression of STAT1Molecular targeted drugs
2019
Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms
Ohmori Y, Nomura T, Fukushima N, Takahashi F, Iwaya T, Koeda K, Nishizuka S, Consortium M. Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms. Journal Of Surgical Oncology 2019, 120: 1154-1161. PMID: 31578743, DOI: 10.1002/jso.25718.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCodonFemaleFollow-Up StudiesGastrectomyGenetic Predisposition to DiseaseGenotypeHumansIncidenceJapanMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPolymorphism, Single NucleotideRisk AssessmentStomach NeoplasmsSurvival RateTumor Suppressor Protein p53ConceptsRelapse-free survivalTP53 codon 72 polymorphismArg/ArgCodon 72 polymorphismGastric cancerOverall survivalHazard ratioHigh-risk patient groupsPostoperative adjuvant chemotherapyRecurrence risk evaluationArg/ProPro/Pro groupAdjuvant chemotherapyT3N0M0 patientsCurative intentStudy cohortPatient groupPro polymorphismEntire observation periodPolymorphism statusPRO groupPatientsArg/CancerPro/
2014
A Compensatory Role of NF-κB to p53 in Response to 5-FU–Based Chemotherapy for Gastric Cancer Cell Lines
Endo F, Nishizuka SS, Kume K, Ishida K, Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K, Wakabayashi G. A Compensatory Role of NF-κB to p53 in Response to 5-FU–Based Chemotherapy for Gastric Cancer Cell Lines. PLOS ONE 2014, 9: e90155. PMID: 24587255, PMCID: PMC3937424, DOI: 10.1371/journal.pone.0090155.Peer-Reviewed Original ResearchMeSH KeywordsAntimetabolites, AntineoplasticCell Line, TumorCodonDrug Resistance, NeoplasmFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansNF-kappa BProtein BindingProtein TransportStomach NeoplasmsTranscription Factor RelATumor Suppressor Protein p53ConceptsGastric cancer cell linesCancer cell linesNF-κBAdjuvant chemotherapyPrediction markersCell linesNF-κB-dependent mannerGastric cancer patientsKnockdown of RelANF-κB bindingArg homozygosityCurative resectionRelapse rateCancer patientsGastric cancerPrediction biomarkersChemotherapyP65 subunitTP53 knockdownChemotherapeutic efficacyProtein levelsCompensatory roleP53Target protein levelsTreatment
2012
Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers
Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers. PLOS ONE 2012, 7: e43236. PMID: 22905237, PMCID: PMC3419205, DOI: 10.1371/journal.pone.0043236.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticBiomarkers, TumorCell Line, TumorChemotherapy, AdjuvantCluster AnalysisColorectal NeoplasmsFluorouracilGene Expression Regulation, NeoplasticHumansImmunohistochemistryMAP Kinase Kinase 4Middle AgedPrognosisRecurrenceRNA, Small InterferingStomach NeoplasmsConceptsAdjuvant chemotherapyNF-κBCancer patientsTissue microarrayProtein expressionColorectal cancer patientsOverall survival rateGastrointestinal tract cancerGastric cancer patientsGastric cancer cell linesCell linesCancer cell linesJNK protein expressionR0 resectionTract cancerColorectal cancerImmunohistochemical examinationClinical significanceSurvival rateRelapse predictionBaseline expressionChemotherapyChemosensitivity markerPatientsGastric